Pediatrics

This year's theme, "Love Your Eyes," focuses on children's vision and eye health.

Educating parents of pediatric patients starts with getting staff on the same page.

Pediatric TINU syndrome is rare, but responds well to treatment.

This study also found that upon discontinuation, myopia development did not rebound, with NVK002 0.01% as a potential long-term treatment for pediatric myopia.

The collective enhances education, research, and quality of life.

The important role eye care providers play in lessening the burden of myopia treatment for pediatric specialists.

A research report compiled by The Vision Council reveals that most parents are aware of myopia but remain in the dark about prevalence and how to prevent progression.

Research presented during the 2023 American Academy of Optometry meeting highlighted the importance of myopia management techniques to control and slow the progression of myopia.

Set your young patients—and their caregivers—up for success in treatment.

Research from Orbis International analyzes the overall wellbeing of children with common childhood vision problems.

Documenting the visual effects and simplifying visual life.

In this part 2 of the pediatric myopia and keratoconus series, Drs Chan and Swartz dive into ortho-k and crosslinking in children.

Johnson & Johnson Vision’s ACUVUE Abiliti brand announces its back-to-school campaign to inform parents about myopia and the growing risk of the disease

Pediatric keratoconus is often more challenging to diagnose, resulting in treatment delay and vision loss.

A recent study found that the use of low-dose atropine drops is ineffective in slowing pediatric myopia progression, contradicting a previous study.

These free eye screenings, exams, and prescription glasses during the third annual program at Hands in 4 Youth Camp Vacamas are in thanks to the partnership of Jonas Philanthropies and Vision to Learn.

Studies suggest that high glycemic load carbohydrate diets may alter the genetic influence of growth of the sclera and choroid, which ultimately can induce permanent changes in the development and progression of myopia.

Optometrists should be aware of the consequences of digital device use beyond myopia.

Investigators reported “an increasing trend in the incidence of eye injuries associated with so-called ‘nonpowder’ guns among children.”

Although the use of atropine is not necessarily novel in the myopia management world, the fact that practitioners may soon have an FDA approved formulation of atropine is new and exciting.

In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.

New research suggests sleep is an additional risk factor affecting myopia onset and progression.

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

In a sham device-controlled, randomized, double-blind clinical trial in China, researchers utilized a device that emits 650 nm red light directly to the retina.

Pediatric glaucoma, although rare, can cause irreversible vision loss and leave children visually impaired if not treated timely and adequately.

Although the 20-20-20 rule is still a solid recommendation, recent studies have provided practitioners with more specific recommendations to help potentially prevent the onset and slow the progression of myopia.

A look back on what happened in optometry during the week of March 20-March 24.

REACH operates with three objectives: 1) eliminate barriers to eye health for school children; 2) improve the quality of school eye health services; and 3) create a positive, sustainable environment at schools where eye health services are provided, ensuring children feel comfortable to access these services.

Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO, shares key takeaways from her SECO 2023 panel discussion, "Myopia management."

Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.